Joel Neal
Medical Oncology · Stanford, CANPI 1790858942
Payments from drug & device makers
Across 378 payments — averaging $16,790 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$2.5M
- Merck$1.2M
- Takeda Pharmaceuticals U.S.A., Inc.$956K
- AstraZeneca$947K
- E.r. Squibb & Sons, L.L.C.$208K
- GSK$206K
- plus $392K from 25 others
Across 1 payment — averaging $637.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$638
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 91 | $2,454,601 |
| Merck | 11 | $1,183,287 |
| Takeda Pharmaceuticals U.S.A., Inc. | 95 | $955,974 |
| AstraZeneca | 19 | $946,944 |
| E.r. Squibb & Sons, L.L.C. | 5 | $208,339 |
| GSK | 44 | $205,727 |
| Exelixis Inc. | 5 | $151,929 |
| AbbVie | 8 | $46,375 |
| Astrazeneca UK Limited | 3 | $30,410 |
| Amgen | 8 | $25,147 |
| Iovance Biotherapeutics, Inc. | 12 | $24,750 |
| Eli Lilly | 8 | $16,984 |
| Janssen Scientific Affairs, LLC | 8 | $14,620 |
| Genentech, Inc. | 2 | $12,745 |
| Gilead | 10 | $12,169 |
| Sanofi | 3 | $9,642 |
| Johnson & Johnson | 11 | $8,775 |
| Genentech USA, Inc. | 9 | $7,159 |
| Taiho Oncology, Inc. | 4 | $5,984 |
| Boehringer Ingelheim International GmbH | 1 | $4,810 |
| Novocure GmbH | 1 | $4,770 |
| Regeneron Healthcare Solutions, Inc. | 2 | $4,585 |
| Regeneron | 2 | $3,635 |
| Blueprint Medicines Corporation | 2 | $2,944 |
| Boehringer Ingelheim | 1 | $2,220 |
| Daiichi Sankyo Inc. | 2 | $702 |
| Viiv Healthcare Company | 1 | $576 |
| Novartis | 6 | $563 |
| Novocure Inc. | 2 | $153 |
| Pfizer | 1 | $58 |
| Jazz Pharmaceuticals Inc. | 1 | $30 |
How this compares
$6,346,608 in reported general payments places this provider in the 95th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Stanford
- Sandhya SrinivasStanford$10.3M
- Melinda TelliStanford$10.3M
- Ranjana AdvaniStanford$7.6M
- Lipika GoyalStanford$5.4M
- Kristen GanjooStanford$4.8M
- Gabriel MannisStanford$3.6M
- Saad Munib Ahmed KhanStanford$3M
- George SledgeStanford$2.1M
- Heather WakeleeStanford$2.1M
- Christopher ChenStanford$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.